Dr. Reddy's Fexofenadine/Pseudoephedrine Tablets Fail Dissolution Specification
Dr. Reddy's Laboratories is recalling Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg Extended-Release Tablets because the tablets failed to meet dissolution specifications, which may affect the drug's effectiveness.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III recall involving a dissolution specification failure. The source text does not report any illnesses, injuries, or deaths. The defect is a manufacturing quality issue that may reduce drug effectiveness but does not pose an immediate safety hazard, placing it in the moderate category per the rubric.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg Extended-Release Tablets USP due to failed dissolution specifications. The affected products include three box sizes: 10-tablet boxes (UPC 343598823355, Lot AC2103328D, Exp. 1/31/2023), 20-tablet boxes (UPC 343598823140, Lot AC2000968C, Exp. 8/31/2022), and 30-tablet boxes (UPC 343598823317, Lots AC2103330C Exp. 1/31/2023 and AC2106452D Exp. 3/31/2023). A total of 9,912 boxes were distributed nationwide in the USA. The tablets were manufactured in India.
When a tablet fails dissolution specifications, the active ingredients may not dissolve properly in the body, potentially reducing the drug's therapeutic effectiveness. Consumers should consult their healthcare provider before discontinuing use of this medication.
The recalling firm is Dr. Reddy's Laboratories, Inc., located in Princeton, New Jersey. This is an FDA Class III recall.
The recalled product
- Product
- Dr. Reddys, Fexofenadine HCl 60 mg & Pseudoephedrine HCl 120 mg Extended-Release Tablets USP, a) 10 tablets per box, UPC 343598823355, b) 20 tablets per box, UPC 343598823140, c) 30 tablets per box, UPC 343598823317, Distributed by: Dr. Reddy's Laboratories, Inc. Princeton, NJ 08
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Hazard
- dissolution-failure
- reduced-efficacy
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot #s: a) (10-count): AC2103328D
- Exp. 1/31/2023. b) (20-count) :AC2000968C
- Exp. 8/31/2022. c) (30-count): AC2103330C
- Exp. 1/31/2023
- AC2106452D
- Exp. 3/31/2023.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27